LTFS
XENE icon

Ladenburg Thalmann Financial Services’s Xenon Pharmaceuticals XENE Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$10K Buy
+750
New +$7.89K ﹤0.01% 4496

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ladenburg Thalmann Financial Services's XENE Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services opened a new position in Xenon Pharmaceuticals (XENE) in Q4 2019: 750 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #4496 among its holdings.

66 funds tracked by Wall St. Rank hold XENE as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 750 shares of Xenon Pharmaceuticals worth $10K as of Q4 2019.
  • Xenon Pharmaceuticals was a new Ladenburg Thalmann Financial Services position in Q4 2019.
  • Xenon Pharmaceuticals made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4496 holding.
  • 66 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.